Edward Fitzgerald
Directeur/Membre du Conseil chez Fog Pharmaceuticals, Inc.
Profil
Edward M.
Fitzgerald is currently a Director at Fog Pharmaceuticals, Inc. He was previously an Independent Director at Akcea Therapeutics, Inc. from 2017 to 2020, and the Chief Financial Officer, Treasurer & Executive VP at ARIAD Pharmaceuticals, Inc. from 2011 to 2016.
Prior to that, he was the Chief Financial Officer, Secretary & Senior VP at AltaRex Medical Corp.
from 1998 to 2002, and a Partner at Arthur Andersen LLP from 1989 to 1992.
Mr. Fitzgerald received his undergraduate degree and MBA from Babson College.
Postes actifs de Edward Fitzgerald
| Sociétés | Poste | Début |
|---|---|---|
Fog Pharmaceuticals, Inc.
 Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Edward Fitzgerald
| Sociétés | Poste | Fin |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/04/2020 |
| ARIAD PHARMACEUTICALS, INC. | Directeur Financier/CFO | 21/03/2016 |
AltaRex Medical Corp.
 AltaRex Medical Corp. Miscellaneous Commercial ServicesCommercial Services Part of Endo International Plc, AltaRex Medical Corp. develops and researches foreign antibodies for cancer and life-threatening disease treatment. The company is based in Edmonton, Canada. AltaRex Medical was acquired by ViRexx Medical Corp., part of Endo International Plc from December 23, 2008 on December 13, 2004 for $22.66 million. | Directeur Financier/CFO | 01/04/2002 |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Corporate Officer/Principal | 01/01/1992 |
Formation de Edward Fitzgerald
| Babson College | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
AltaRex Medical Corp.
AltaRex Medical Corp. Miscellaneous Commercial ServicesCommercial Services Part of Endo International Plc, AltaRex Medical Corp. develops and researches foreign antibodies for cancer and life-threatening disease treatment. The company is based in Edmonton, Canada. AltaRex Medical was acquired by ViRexx Medical Corp., part of Endo International Plc from December 23, 2008 on December 13, 2004 for $22.66 million. | Commercial Services |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
